Niagen Bioscience: A Breakout Quarter That Now Faces Its Biggest Market Shift In Years

Niagen Bioscience delivered record Q3 revenue, rising 33% year-over-year, driven by strong Tru Niagen demand and accelerating distribution partnerships. Gross margin expanded to 64.5%, while operating income and adjusted EBITDA grew sharply, reflecting improving scale and cost discipline. Cash from operations already exceeded last year's total, supporting a new $10 million share repurchase program.

Seeking Alpha • Nov 15, 2025

Niagen Bioscience Launches Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. Featuring Niagen® (Patented Nicotinamide Riboside)

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of Tru Niagen® Beauty, the first-ever beauty supplement in the US featuring Niagen (patented nicotinamide riboside or NR) — the most efficient, effective, and high quality NAD+ booster available. Tru Niagen Beauty expands Niagen Bioscience's leadership in NAD+ skincare science with a cellul.

Business Wire • Nov 13, 2025

Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today shared promising results from the first-of-its-kind clinical trial published today in The Lancet peer-reviewed journal eClinicalMedicine demonstrating that daily supplementation with Niagen®, Niagen Bioscience's patented nicotinamide riboside (NR) ingredient, significantly increased NAD+ levels and improved exe.

Business Wire • Nov 13, 2025

Niagen Bioscience Announces $10 Million Share Repurchase Program

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Board of Directors has approved a share repurchase program under which the Company is authorized to repurchase up to $10 million of outstanding common stock over approximately 24 months (the “Program”). “We believe Niagen Bioscience is an excellent investment and the Program is a compelling u.

Business Wire • Nov 6, 2025

Niagen Bioscience, Inc. (NAGE) Q3 2025 Earnings Call Transcript

Niagen Bioscience, Inc. ( NAGE ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Kendall Knysch - Head of Media Relations & Partnerships Robert Fried - CEO & Director Ozan Pamir - CFO & Principal Accounting Officer Conference Call Participants Destiny Buch - Ladenburg Thalmann & Co. Inc., Research Division Susan Anderson - Canaccord Genuity Corp., Research Division Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division Sean McGowan - ROTH Capital Partners, LLC, Research Division Presentation Operator Ladies and gentlemen, thank you for standing by, and welcome to the Niagen Biosciences, Inc. Third Quarter of 2025 Earnings Conference Call.

Seeking Alpha • Nov 4, 2025

Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the third quarter of 2025. Third Quarter 2025 Financial Highlights Compared to Prior Year Period Total net sales increased 33% to $34.0 million, with Tru Niagen® sales of $26.0 million, up 44%. Gross margin increased 100 basis points to 64.5%. Sales and marketing expense as a percentage of net sales was 25.8%, an improvement of 170 basis points. Net income of $4.6 million or $0.06 earnings.

Business Wire • Nov 4, 2025

Niagen Bioscience (NAGE) Surpasses Q3 Earnings and Revenue Estimates

Niagen Bioscience (NAGE) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.02 per share a year ago.

Zacks Investment Research • Nov 5, 2025

Niagen Bioscience (NAGE) Reports Next Week: What to Expect

Niagen Bioscience (NAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 28, 2025

Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Tuesday, November 4, 2025, at 4:30 p.m. ET to discuss its financial results for the third quarter 2025, which ended September 30, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on Tuesday, November.

Business Wire • Oct 21, 2025

Niagen Bioscience Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced it has increased its full-year 2025 net sales outlook to 25% to 30% year-over-year growth from 22% to 27%. “Elevating NAD+ is critical for health, especially as we age, and greater attention to this important area of science is valuable for public health and for Niagen Bioscience,” remarked Rob Fried,.

Business Wire • Oct 6, 2025